Repurposed Hepatitis C Drug Bemnifosbuvir Shows Potential to Halt Global Hepatitis E Mortality

International researchers find that the drug bemnifosbuvir effectively blocks hepatitis E replication, offering hope for a virus with no approved treatment.

By: AXL Media

Published: Apr 6, 2026, 9:20 AM EDT

Source: Information for this report was sourced from ScienceDaily

A Potential Breakthrough for Untreated Viral Infections

Scientific researchers have identified a promising new candidate to combat the hepatitis E virus, a pathogen that currently lacks any approved vaccine or targeted therapeutic intervention. The discovery centers on bemnifosbuvir, a compound that has demonstrated a remarkable ability to prevent the virus from reproducing within the body. According to the research team, this development is particularly significant because the virus is responsible for approximately 70,000 deaths every year and infects millions of individuals globally.

The Mechanism of Genetic Disruption

Bemnifosbuvir belongs to a specific class of synthetic molecules known as nucleotide or nucleoside analogues. Dr. Mara Klöhn of Ruhr University Bochum explains that these compounds are designed to mimic the natural building blocks of genetic material. When the virus attempts to replicate, it mistakenly incorporates these synthetic analogues into its machinery, effectively stalling the reproduction process. This mechanism allows the drug to neutralize the viral threat while ensuring that the surrounding healthy host cells remain unharmed.

Screening for Antiviral Efficacy

The discovery resulted from an intensive screening process involving an international team from institutions in Germany and China. To identify the most effective treatments, scientists utilized a library of roughly 500 antiviral compounds and tested them against a bio-engineered version of the hepatitis E virus. Jungen Hu of Heidelberg University reports that the researchers used a modified virus that produces a fluorescent signal, allowing them to visually confirm when a drug successfully halted viral activity in cell cultures.